Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy

Journal of Neuromuscular Diseases

Volumn 4, Issue 2, 2017, Pages 139-145

  Young, Courtney S ^a   Mokhonova, Ekaterina ^a,b   Quinonez, Marbella ^a,b   Pyle, April D ^a,b   Spencer, Melissa J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

animal models; CRISPR; Duchenne muscular dystrophy; gene editing; mice

Indexed keywords

DYSTROPHIN; DMD PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; EXON; FEMALE; GENE DELETION; GENE EDITING; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CRISPR CAS SYSTEM; DISEASE MODEL; GENE THERAPY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; GENE EDITING; GENETIC THERAPY; HEK293 CELLS; HUMANS; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 85032567494     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-170218     Document Type: Article

References (17)

1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, Al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304-13. doi: 10. 1002/ana. 23528
2. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of theDMDlocus. Genomics. 1988;2(1):90-5.
3. Aartsma-Rus A, van Ommen G-JB. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA. 2007;13(10):1609-24. doi: 10. 1261/rna. 653607
4. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-Guided Human Genome Engineering via Cas9. Science. 2013;339:823-7. doi: 10. 1126/science. 1232033
5. Cong L, Ran AF, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. 2013;339:819-23. doi: 10. 1126/science. 1231143
6. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337:816-22. doi: 10. 1126/science. 1225829
7. 't Hoen PAC, de Meijer EJ, Boer JM, Vossen RHAM, Turk R, Maatman RGHJ, et al. Generation and characterization of transgenic mice with the full-length human DMD gene. J Biol Chem. 2008;283(9):5899-907. doi: 10. 1074/jbc. M709410200
8. Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P, Moran JL, et al. Latent TGF-binding protein 4 modifies muscular dystrophy in mice. JCI. 2009;119(12):3703-12. doi: 10. 1172/JCI39845
9. Coley WD, Bogdanik L, Vila MC, Yu Q, van der Meulen JH, Rayavarapu S, et al. Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet. 2016;25(1):130-45. doi: 10. 1093/hmg/ddv460
10. Swaggart KA, Demonbreun AR, Vo AH, Swanson KE, Kim EY, Fahrenbach JP, et al. Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. PNAS. 2014;111(16):6004-9. doi: 10. 1073/pnas. 1324242111
11. Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-DerivedMuscle Cells. Cell Stem Cell. 2016;18(4):533-40. doi: 10. 1016/j. stem. 2016. 01. 021
12. DiFranco M, Quinonez M, Capote J, Vergara J. DNA transfection of mammalian skeletal muscles using in vivo electroporation. JoVE. 2009;(32):1-7. doi: 10. 3791/1520
13. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014;516(7531):423-7. doi: 10. 1038/nature13902
14. Thanh LT, Nguyen TM, Helliwell TR, Morris GE. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet. 1995;56(3): 725-31.
15. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-23. doi: 10. 1126/science. 1231143
16. Man N, Morris GE. Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet. 1993;52:1057-66.
17. Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, SilvaO, et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med. 2012;4:164ra160. doi: 10. 1126/scitranslmed. 3005054